EndoClot Plus, Inc. (EPI) announced the U.S. Food and Drug Administration (FDA) has approved EndoClot Polysaccharide Hemostatic System (EndoClot PHS), an innovative product that assists Gastroenterologists to stop bleeding rapidly and reliably. EndoClot PHS is expected to be commercially available in the United States by May 2021.
EndoClot PHS is a single use device including a starch-based powder hemostat that is applied directly to the bleeding site through a flexible endoscope. The patented Absorbable Modified Polymer (AMP) powder can quickly concentrate the blood to accelerate the normal physiological clotting process.
